Novo Nordisk
About the organisation
[AI generated] Novo Nordisk is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark. Founded in 1923, it specializes in treatments for diabetes, obesity, hemophilia, and other chronic conditions. The company is a global leader in insulin production and develops drugs such as semaglutide. It operates in over 80 countries and is one of Europe's most valuable corporations by market capitalization.
What the listing means
Novo Nordisk appeared on the fulcrumsec leak site on 16 June 2026. Groups publish a victim once negotiations stall or as pressure during them, so a listing usually means data was already exfiltrated — the attack itself is dated 07 June 2026, 9 days before the listing. This group has not published new claims in the last 30 days.
Recommended actions
- Treat any unsolicited message referencing Novo Nordisk as suspicious — leaked data gets weaponised for phishing within days.
- If you hold an account on novonordisk.com, change that password now, update it anywhere you reused it, and enable two-factor authentication.
- Other Healthcare organisations should review this group's known TTPs and validate detection coverage against them.
- Watch for follow-on extortion: stolen data is often re-leaked or resold after the initial listing.
- A leak-site listing is a claim made by the attacker, not a confirmed breach — check the organisation's own disclosures before acting on it.
Leak-site evidence
Listing URL https://www.ransomware.live/id/Tm92byBOb3JkaXNrQGZ1bGNydW1zZWM=
Show leak-site screenshot
Captured from the group's extortion site. It may contain the victim's data or the attacker's messaging.
